3-D Matrix FCF Margin
The Free Cash Flow Margin of 3-D Matrix (7777.T) as of Jul 30, 2026 is -24.90 %. In the previous year, Free Cash Flow Margin was -41.50 % — a change of -40.00% (higher).
Get this data via API
Financial Data API
FCF Margin
-24.90 %
YoY
-40.00%
Last updated:
Free Cash Flow Margin of 3-D Matrix is 2026 -24.90 % . Free Cash Flow Margin of 3-D Matrix was 2025 -41.50 % . It decreases by -40.00% higher compared to the previous year.
Access this data via the Eulerpool API
3-D Matrix Stock analysis
What does 3-D Matrix do? 3-D Matrix Ltd is a company specialized in the development and manufacturing of innovative products in the field of biotechnology. Since its founding in 1998, the company has gained recognition for its outstanding research and development results and is now one of the leading companies in the industry.
The history of 3-D Matrix Ltd began in 1998 when a group of scientists from Japan made a groundbreaking discovery in the field of materials science. They discovered that a certain material has a unique structure that allows cells and tissues to be cultivated in a more natural way than was previously possible. This discovery formed the basis for the founding of 3-D Matrix Ltd.
The business model of 3-D Matrix Ltd is to use its innovative technology and unique products in various areas of biotechnology. The company's three main divisions are regenerative medicine, cell culture, and medical devices.
In the field of regenerative medicine, 3-D Matrix Ltd is working to improve the healing of tissue damage and diseases. The company has developed a range of products that enable the effective and natural regeneration of the body's own cells and tissues. These products are used in the treatment of various diseases such as diabetes, arthritis, or tumors.
In the cell culture division, 3-D Matrix Ltd offers products that enable cells to be cultured in a natural and effective way. The company has developed a range of innovative cell culture products that allow cells to be grown in a three-dimensional environment that closely resembles the natural environment in the body. These products are used in drug research and development, vaccine production, and personalized medicine.
In the medical devices division, 3-D Matrix Ltd offers a range of products that are used in the performance of medical procedures. These products have been developed to improve the safety and effectiveness of medical procedures while reducing recovery time. These include products such as collagen membranes, collagen sponges, and brushes, which are used in plastic surgery, dentistry, and orthopedics.
Some of the products offered by 3-D Matrix Ltd include collagen membranes, collagen sponges, collagen brushes, collagen fibrils, and collagen hydrogels. All of these products have been developed using 3-D Matrix Ltd's unique material technology and provide a natural and effective solution for a variety of medical applications.
In conclusion, 3-D Matrix Ltd is a company dedicated to the development and manufacturing of innovative products in the field of biotechnology. The company has developed a unique technology that allows for the natural and effective cultivation and regeneration of cells and tissues. The products of 3-D Matrix Ltd are used in various areas of biotechnology, such as regenerative medicine, cell culture, and medical devices, and provide a natural and effective solution for a variety of medical applications. 3-D Matrix is one of the most popular companies on Eulerpool.
Frequently Asked Questions about 3-D Matrix stock
Free Cash Flow Margin of 3-D Matrix is -24.90 % in 2026.
Access this data via the Eulerpool API
Margins — 3-D Matrix
All Key Metrics — 3-D Matrix
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth